Group 1 - The core point of the article is that Yisi Biopharma (Shanghai) Co., Ltd. is considering an IPO in Hong Kong and is currently collaborating with advisors to prepare for the listing, with details on the scale and timing still under discussion [1] - Yisi Biopharma was established in 2020 and is headquartered in Shanghai, focusing on biopharmaceuticals for brain diseases, specifically targeting central nervous system disorders such as epilepsy, insomnia, and Parkinson's disease [1] - The company aims to translate cutting-edge science into innovative solutions that benefit patients [1] Group 2 - Yisi Biopharma has received investments from various notable entities, including Tonghe Yucheng, Ruentex Group, KB Investment, WTT Investment, Mubadala Investment Company, HBM Healthcare Investments, Goldman Sachs, and 6Dimensions Capital [1]